Treating hypertension in kidney transplant recipients
|
|
- Daisy Gilmore
- 5 years ago
- Views:
Transcription
1 Treating hypertension in kidney transplant recipients Mark Mitsnefes, MD, MS Professor of Pediatrics Director, Clinical Translational Research Center Cincinnati Children s Hospital Medical Center University of Cincinnati Valencia, February 10, 2018
2 What do we KNOW WELL about hypertension in pediatric kidney transplant recipients?
3 Hypertension is common NAPRTCS 2003 NAPRTCS 2014 Use of antihypertensive medications
4 BP control following kidney transplant is not optimal All current UK kidney transplant recipients (n=428) Data collected at 6 months, 1, 2 and 5 years post transplant 25-27% had BP >95 th percentile 48-60% were using antihypertensives 30-35% had BP >95 th percentile Sinha et al, NDT 2012
5 Hypertension and uht were more prevalent in young adult KTRs (86.4 and 75.8%) than in paediatric KTRs (62.7 and 38.3%) according to the KDIGO definition. Dobrowolski et al, NDT 2016 HTN I: BP <90 th % or >130/80 (>18y) - KDIGO HTN II: BP >95 th % or >140/90 (>18y) - 4 th report and WHO
6 Ambulatory HTN is common % 90 Prevalence of ambulatory HTN % Lingens 1997 Mateucci 1999 Morgan 2001 Seeman 2004 Ferraris 2007 Basiratnia 2010 Paripovic 2011 Cameron 2014 Hamdani 2017
7 What else do we know? Hypertension is associated with LVH >10 studies over last decade Controlled BP improves LVH* Hypertension is associated with cimt >10 studies over last decade Controlled BP improves cimt* Hypertension is associated with: Allograft dysfunction Allograft failure # *Krmar s group (Ped. Transplant 2008, 2011; AJH 2014) *Litwin et al (NDT 2008) # Mitsnefes et al (J. Peds 2003); Hamdani et al (Ped. Transplant 2017)
8 Mean BP <95 th percentile or Mean BP >95 th percentile No difference in allograft function
9 There are many causes of HTN after kidney transplant Acute rejection Chronic rejection/glomerulopathy Graft artery stenosis Native kidneys Obesity Sodium/water retention, Pick your poison Graft dysfunction (CKD) Immunosuppressive drugs corticosteroids, cyclosporine, tacrolimus
10 HTN post transplant: Conclusion #1 Very prevalent despite overall better transplant outcome Multifactorial causes Typically mild to moderate Frequently undertreated despite frequent follow up Monotherapy frequently ineffective; usually requires multiple drugs to control Associated with intermediate CV outcomes
11 Why is it so difficult to control BP post transplant? Provider? Disease? OR We care for complicated patients within a complex system that wasn t designed to address the difficult problems we encounter Courtesy of David Hooper
12 The knowledge of what to do in order to effectively assess and treat uncontrolled BP The knowledge of how to implement this care reliably, in the context of the complex system of clinical care Pediatr Nephrol 2016
13 Evidence for CCM in Managing Hypertension 2013: Jaffe et. al. Improved blood pressure control associated with a large-scale hypertension program. JAMA 310: (n=60,000) Achieved BP control in 80% of patients (baseline 43%) in 9 years 2013: Margolis et al. JAMA 310:46 56 (n=450) Achieved BP control in 71% of subjects (57% control group)
14 How to apply CCM to manage kidney transplant recipient?
15
16 System to Improve BP Control Aim BP Control for Kidney Transplant Recipients KEY DRIVERS Measurement and Classification Appropriate Therapy Assessment of Response Hypertension Causing Meds Effective Self- Management CARE MODEL SYSTEM SUPPORTS Registry to track care and outcomes Decision Support Planned care (previsit planning) Population Management Self-Management Support Hooper, Mitsnefes, Ped. Nephrol, 2015
17 Proper BP Measurement and Documentation Height Proper cuff size Manual BP (not oscillometric) Seated position Resting for 5 minutes Upper extremity Mean of two readings Recording Technique Auto calculated mean
18 Can systematic measurement of arm circumference lead to improvement in Process choosing correct BP cuff? Arm circumference Outcome Correct BP cuff
19 Missing Components Run Chart: LIB Missing BP components in Most Recent Quarter: Sep-Dec Mean of Two Readings Rested 5 min Arm Circumference Cuff Size Height BP Method 90% Cutoff
20 Physician BP classification Auto-calculated mean BP Auto-calculated percentiles RN entered 90 th percentile cut-off Auto-calculated 95 th percentile cut-off RN entered 99 th percentile + 5 cut-off Physician classifies BP using KDIGO targets * < 18 y.o.: <90 th %tile and 130/80 * 18 y.o.: <130/80
21 Ambulatory BP Monitoring Process Pt. performs test and returns monitor Staff extracts discrete data from monitor and enters into discrete fields in EHR (DocFlowsheets) Output: Letter automated from discrete fields. Data readily available for analysis. MD interprets discrete data, enters diagnosis/interpretation into discrete fields in EHR (DocFlowsheets)
22 Outputs ABPM DocFlowsheet ABPM letter in EPIC
23 Patient has at least one ABPM in last 13 months regardless of its results
24 System to Improve BP Control ABPM? Aim BP Control for Kidney Transplant Recipients KEY DRIVERS Measurement and Classification Appropriate Therapy Assessment of Response Hypertension Causing Meds Effective Self- Management CARE MODEL SYSTEM SUPPORTS Registry to track care and outcomes Decision Support Planned care (previsit planning) Population Management Self-Management Support Hooper, Mitsnefes, Peds Neph, 2015
25 221 children with kidney transplant from 6 centers BP was classified according to 2014 AHA Normal office and mean ABP, But BP load > 25% Transplantation, 2017
26 Simplified groups (4 categories) Classification based on 24-hour BP load 25% 23% 63% European guidelines Classification based on 24-hour mean BP > 95 th % 32% 51% AMBULATORY HYPERTENSION 11% CKiD suggestion MASKED HYPERTENSION 13% WCH 3% 13% 73% NORMAL BP 73% No consensus
27 System to Improve BP Control Aim BP Control for Kidney Transplant Recipients KEY DRIVERS Measurement and Classification Appropriate Therapy Assessment of Response Hypertension Causing Meds Effective Self- Management CARE MODEL SYSTEM SUPPORTS Registry to track care and outcomes Decision Support Planned care (previsit planning) Population Management Self-Management Support Hooper, Mitsnefes, Peds Neph, 2015
28 Appropriate therapy 2009 <90 th percentile or 130/80 Any class ACEI/ARB if proteinuric
29 Appropriate therapy 2012
30 CCB, ACEI, others? FAVORIT: Retrospective CCB vs. not N=4110 (1436) on CCB Chlorthalidone vs amlodipine A single-center, prospective, randomized, crossover, open-label, non-inferiority study; n=41 each group ABPM: baseline and at 8 weeks No difference in BP control No difference in survival Chlorthalidone Reduced proteinuria and edema Temporarily allograft function and serum Uric acid and Hg A1C Weinrauch et al, Int J Nep and Renovasc Dis 2018 Moes et al, AJKD 2017
31 8 trials (n=1,502) Conclusion No advantage No disadvantage Death Graft failure Doubling creatinine Use on a case-by-case basis Hiremath et al, AJKD 2016
32 System to Improve BP Control Aim BP Control for Kidney Transplant Recipients KEY DRIVERS Measurement and Classification Appropriate Therapy Assessment of Response Hypertension Causing Meds Effective Self- Management CARE MODEL SYSTEM SUPPORTS Registry to track care and outcomes Decision Support Planned care (previsit planning) Population Management Self-Management Support Hooper, Mitsnefes, Peds Neph, 2015
33 Therapy Escalation and Follow-up Escalate therapy according to protocol Follow up BP in 2-4 weeks (at home or in clinic)
34 System to Improve BP Control Aim BP Control for Kidney Transplant Recipients KEY DRIVERS Measurement and Classification Appropriate Therapy Assessment of Response Hypertension Causing Meds Effective Self- Management CARE MODEL SYSTEM SUPPORTS Registry to track care and outcomes Steroid Adherence avoidance Steroid Diet minimization CNI Decision trough monitoring Support Physical activity Smoking Planned care (previsit Alcohol planning) Sex Population Management Self-Management Support Hooper and Mitsnefes, Peds Neph, 2015
35 Hooper, Mitsnefes, Peds Neph, 2015
36 How well are we doing by implementing systematic approach?
37 BP Control Run Chart Percent of patients with *Well-controlled Systolic and Diastolic BP Jan-2014 to Nov-2017 KDIGO targets * < 18 y.o.: <90 th %tile and 130/80 * 18 y.o.: <130/80 Completed on 12/14/2017 by F. Mostajabi. James M. Anderson Center for Health System
38 ABPM Control Run Chart >90% with NORMAL 24-hour MAP
39 > 80% with NORMAL nocturnal BP
40 Team work!
Chronic Pediatric Hypertension
Chronic Pediatric Hypertension Nephrology Grand Round 3/13/2015 Mahmoud Kallash M.D Outline Definition of hypertension (HTN) Challenges in diagnosing HTN Epidemiology Causes and evaluation of HTN Management
More informationTodd S. Perlstein, MD FIFTH ANNUAL SYMPOSIUM
Todd S. Perlstein, MD FIFTH ANNUAL SYMPOSIUM Faculty Disclosure I have no financial interest to disclose No off-label use of medications will be discussed FIFTH ANNUAL SYMPOSIUM Recognize changes between
More informationObjectives. Describe results and implications of recent landmark hypertension trials
Hypertension Update Daniel Schwartz, MD Assistant Professor of Medicine Associate Medical Director of Heart Transplantation Temple University School of Medicine Disclosures I currently have no relationships
More informationImportance of Ambulatory Blood Pressure Monitoring in Adolescents
Importance of Ambulatory Blood Pressure Monitoring in Adolescents Josep Redon, MD, PhD, FAHA Internal Medicine Hospital Clinico Universitario de Valencia University of Valencia CIBERObn Instituto de Salud
More informationHypertension and Cardiovascular Disease
Hypertension and Cardiovascular Disease Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic,
More informationDifficult-to-Control & Resistant Hypertension. Anthony Viera, MD, MPH, FAHA Professor and Chair
Difficult-to-Control & Resistant Hypertension Anthony Viera, MD, MPH, FAHA Professor and Chair Objectives Define resistant hypertension Discuss evaluation strategy for patient with HTN that appears difficult
More informationHypertension with Comorbidities Treatment of Metabolic Risk Factors in Children and Adolescents
Hypertension with Comorbidities Treatment of Metabolic Risk Factors in Children and Adolescents Stella Stabouli Ass. Professor Pediatrics 1 st Department of Pediatrics Hippocratio Hospital Evaluation of
More informationKDIGO Controversies Conference on Blood Pressure in CKD
KDIGO Controversies Conference on Blood Pressure in CKD September 7-10, 2017 Edinburgh, Scotland Kidney Disease: Improving Global Outcomes (KDIGO) is an international organization whose mission is to improve
More informationLessons learned from AASK (African-American Study of Kidney Disease and Hypertension)
Lessons learned from AASK (African-American Study of Kidney Disease and Hypertension) Janice P. Lea, MD, MSc, FASN Professor of Medicine Chief Medical Director of Emory Dialysis ASH Clinical Specialist
More informationRESISTANT HYPERTENSION
RESISTANT HYPERTENSION John D. Bisognano, MD PhD Professor of Medicine / Cardiology President-Elect, American Society of Hypertension Director, Outpatient Cardiology University of Rochester RESISTANT HYPERTENSION
More informationBlood Pressure Control According to the Prevalence of Diabetes in Renal Transplant Recipients
Blood Pressure Control According to the Prevalence of Diabetes in Renal Transplant Recipients E. Zbroch, J. Malyszko, I. Glowinska, D. Maciorkowska, G. Kobus, and M. Mysliwiec ABSTRACT Hypertension is
More informationWhat s In the New Hypertension Guidelines?
American College of Physicians Ohio/Air Force Chapters 2018 Scientific Meeting Columbus, OH October 5, 2018 What s In the New Hypertension Guidelines? Max C. Reif, MD, FACP Objectives: At the end of the
More informationADVANCES IN MANAGEMENT OF HYPERTENSION
Prevalence 29%; Blacks 33.5% About 72.5% treated; 53.5% uncontrolled (>140/90) Risk for poor control: Latinos, Blacks, age 18-44 and 80,
More informationDisclosures. Goals. Blood Pressure UPDATE ON HYPERTENSION: NM PEDS SOCIETY WYLDER LECTURES- CRAIG WONG MD AUG 28, 2016
Disclosures UPDATE ON HYPERTENSION: NM PEDS SOCIETY WYLDER LECTURES- CRAIG WONG MD AUG 28, 2016 Craig Wong MD MPH, Support from NIH: UO1 DK 066174 - CKiD RO1 DK 082394 -PediGFR UM1DK100866 - CureGN UpToDate:
More informationDISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose.
JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES Tiffany Dickey, PharmD Assistant Professor, UAMS COP Clinical Pharmacy Specialist, Mercy Hospital Northwest AR DISCLOSURE I
More informationPreventing and Treating High Blood Pressure
Preventing and Treating High Blood Pressure: Finding the Right Balance of Integrative and Pharmacologic Approaches Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Blood Pressure
More informationHypertension Update. Mayo Clinic 90 th Annual Clinical Reviews November 2 nd and 16 th, 2016
Mayo Clinic 90 th Annual Clinical Reviews November 2 nd and 16 th, 2016 Hypertension Update Vincent J. Canzanello, M.D. Consultant, Division of Nephrology and Hypertension Professor or Medicine College
More informationEgyptian Hypertension Guidelines
Egyptian Hypertension Guidelines 2014 Egyptian Hypertension Guidelines Dalia R. ElRemissy, MD Lecturer of Cardiovascular Medicine Cairo University Why Egyptian Guidelines? Guidelines developed for rich
More informationADVANCES IN MANAGEMENT OF HYPERTENSION
Advances in Management of Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Prevalence 29%; Blacks 33.5%
More informationEvaluation and Management of Hypertension in Women. Vesna D. Garovic, M.D. Moscow, Russia, December 2016
Evaluation and Management of Hypertension in Women Vesna D. Garovic, M.D. Moscow, Russia, December 2016 2016 MFMER 3508058-1 Women are not small men There is nothing as powerful as an idea whose time has
More information가정혈압의활용 CARDIOVASCULAR CENTER. Wook Bum Pyun M.D., Ph.D. HOME BLOOD PRESSURE MONITORING. Ewha Womans University, school of Medicine
가정혈압의활용 HOME BLOOD PRESSURE MONITORING CARDIOVASCULAR CENTER Wook Bum Pyun M.D., Ph.D. pwb423@ewha.ac.kr Ewha Womans University, school of Medicine Non-Invasive Blood Pressure Measurement 5-20% Resistant
More informationJared Moore, MD, FACP
Hypertension 101 Jared Moore, MD, FACP Assistant Program Director, Internal Medicine Residency Clinical Assistant Professor of Internal Medicine Division of General Medicine The Ohio State University Wexner
More informationNew Hypertension Guideline Recommendations for Adults July 7, :45-9:30am
Advances in Cardiovascular Disease 30 th Annual Convention and Reunion UERM-CMAA, Inc. Annual Convention and Scientific Meeting July 5-8, 2018 New Hypertension Guideline Recommendations for Adults July
More informationHypertension Putting the Guidelines into Practice
Hypertension 2017 Putting the Guidelines into Practice Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or
More informationhypertension Head of prevention and control of CVD disease office Ministry of heath
hypertension t. Samavat MD,Cadiologist,MPH Head of prevention and control of CVD disease office Ministry of heath RECOMMENDATIONS FOR HYPERTENSION DIAGNOSIS, ASSESSMENT, AND TREATMENT Definition of hypertension
More informationHypertension Putting the Guidelines into Practice
Hypertension 2017 Putting the Guidelines into Practice Disclosures Relationships with commercial interests: Grants/Research Support: Speakers Bureau/Honoraria: Consulting Fees: Data Safety and Monitoring:
More informationReference Values and Simplified Methods for Interpretation of Blood Pressure in Children and Adolescents
Reference Values and Simplified Methods for Interpretation of Blood Pressure in Children and Adolescents Simonetti G.D. Istituto Pediatrico della Svizzera Italiana Ente Ospedaliero Cantonale e Università
More informationDr Doris M. W Kinuthia
Dr Doris M. W Kinuthia Objectives Normal blood pressures in children Measurement of blood pressure in children Aetiology of Hypertension in children Evaluation of children with hypertension Treatment of
More informationABPM vs. office blood pressure to define blood pressure control in treated hypertensive paediatric renal transplant recipients
Pediatr Transplantation 2007: 11: 24 30 Copyright Ó 2007 Blackwell Munksgaard Pediatric Transplantation DOI: 10.1111/j.1399-3046.2006.00595.x ABPM vs. office blood pressure to define blood pressure control
More informationManaging Hypertension in 2018
MANAGING HYPERTENSION IN 2018 How Do We Work With Conflicting Data and Conflicting Guidelines? Disclosure No relevant financial relationships Robert B. Baron, MD MS Professor and Associate Dean UCSF School
More informationRenal Denervation. by Walead Latif, DO, MBA, CPE Assistant Clinical Professor Rutgers Medical School
Renal Denervation by Walead Latif, DO, MBA, CPE Assistant Clinical Professor Rutgers Medical School Disclosure Information ACOI Annual Meeting I have the following financial relationships to disclose:
More informationPrevention of Heart Failure: What s New with Hypertension
Prevention of Heart Failure: What s New with Hypertension Ali AlMasood Prince Sultan Cardiac Center Riyadh 3ed Saudi Heart Failure conference, Jeddah, 13 December 2014 Background 20-30% of Saudi adults
More informationManagement of Lipid Disorders and Hypertension: Implications of the New Guidelines
Management of Lipid Disorders and Hypertension Management of Lipid Disorders and Hypertension: Implications of the New Guidelines Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine
More informationOCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA
OMED 17 OCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA 29.5 Category 1-A CME credits anticipated ACOFP / AOA s 122 nd Annual Osteopathic Medical Conference & Exposition ACOFP - The Heart of the Matter - An Evidence
More informationModern Management of Hypertension
Modern Management of Hypertension Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Hypertension Prevalence
More informationNephrology Potpourri March 22, 2017
Nephrology Potpourri March 22, 2017 http://soulscape.asia/give-flowers-more-life-by-making-your-own-potpourri Kantima Phisitkul, MD Clinical Assistant Professor Renal Diseases and Hypertension Division
More informationWhite coat and masked hypertension
White coat and masked hypertension Conflict of interest Support from Spacelabs, Microlife. Honoraria from Novartis, Elpen, Boeringer-Ingelheim, CANA, Lilly, MSD, Sanofi, Menarini, Ciezi, Astra-Zeneca.
More informationModern Management of Hypertension: Where Do We Draw the Line?
Modern Management of Hypertension: Where Do We Draw the Line? Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Blood Pressure
More informationAdherence to Hypertension Visit Protocol Description: % of patients with HTN who are being monitored through follow up visits according to guidelines, based on "days since last BP", which looks back from
More informationJNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults
JNC 8 2014 Evidence-Based Guidelines for the Management of High Blood Pressure in Adults Table of Contents Why Do We Treat Hypertension? Blood Pressure Treatment Goals Initial Therapy Strength of Recommendation
More informationManagement of High Blood Pressure in Adults
Management of High Blood Pressure in Adults Based on the Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC8) James, P. A. (2014, February 05). 2014 Guideline for Management
More information4/4/17 HYPERTENSION TARGETS: WHAT DO WE DO NOW? SET THE STAGE BP IN CLINICAL TRIALS?
HYPERTENSION TARGETS: WHAT DO WE DO NOW? MICHAEL LEFEVRE, MD, MSPH PROFESSOR AND VICE CHAIR DEPARTMENT OF FAMILY AND COMMUNITY MEDICINE UNIVERSITY OF MISSOURI 4/4/17 DISCLOSURE: MEMBER OF THE JNC 8 PANEL
More informationHypertension Update 2016 AREEF ISHANI, MD MS CHIEF OF MEDICINE MINNEAPOLIS VA MEDICAL CENTER PROFESSOR OF MEDICINE UNIVERSITY OF MINNESOTA
Hypertension Update 2016 AREEF ISHANI, MD MS CHIEF OF MEDICINE MINNEAPOLIS VA MEDICAL CENTER PROFESSOR OF MEDICINE UNIVERSITY OF MINNESOTA Case 1 What should be your BP goal for an elderly (> 75 yrs of
More informationHYPERTENSION: ARE WE GOING TOO LOW?
HYPERTENSION: ARE WE GOING TOO LOW? George L. Bakris, M.D.,F.A.S.N.,F.A.S.H., F.A.H.A. Professor of Medicine Director, ASH Comprehensive Hypertension Center University of Chicago Medicine Chicago, IL USA
More informationMODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure. No relevant financial relationships. Blood Pressure and Risk
MODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure No relevant financial relationships Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu
More informationHTN talk_l Davis_ /28/2018
1 2 GUIDELINES PUBLISHED AHEAD OF PRINT NOV 13, 2017 = SAME DAY AS PUBLIC PRESENTATION LESLIE L DAVIS, PHD, RN, ANP-BC, FPCNA, FAANP, FAHA The New Guidelines Have Been Published! Whelton PK, Carey RM,
More informationNone. Disclosure: Relationships with Industry Conflicts of Interests. Learning Objectives: Participants will be able to:
2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC 8) James W. Shaw, MD Memorial Lecture
More informationHYPERTENSION GUIDELINES WHERE ARE WE IN 2014
HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 Donald J. DiPette MD FACP Special Assistant to the Provost for Health Affairs Distinguished Health Sciences Professor University of South Carolina University
More informationHypertension (JNC-8)
Hypertension (JNC-8) Southern California University of Health Sciences Physician Assistant Program Management and Treatment of Hypertension April 17, 2018, presented by Ezra Levy, Pharm.D.! The 8 th Joint
More informationBlood Pressure Monitoring in Chronic Kidney Disease
Blood Pressure Monitoring in Chronic Kidney Disease Aldo J. Peixoto, MD FASN FASH Associate Professor of Medicine (Nephrology), YSM Associate Chief of Medicine, VACT Director of Hypertension, VACT American
More informationHypertension in Geriatrics. Dr. Allen Liu Consultant Nephrologist 10 September 2016
Hypertension in Geriatrics Dr. Allen Liu Consultant Nephrologist 10 September 2016 Annual mortality (%) Cardiovascular Mortality Rates are Higher among Dialysis Patients 100 10 1 0.1 0.01 0.001 25-34
More informationChapter 16: Hypertension, Dyslipidemias, Tobacco Use, and Obesity
Chapter 16: Hypertension, Dyslipidemias, Tobacco Use, and Obesity 16.1: HYPERTENSION 16.1.1: We recommend measuring blood pressure at each clinic visit. (1C) 16.1.2: We suggest maintaining blood pressure
More informationHypertension and the SPRINT Trial: Is Lower Better
Hypertension and the SPRINT Trial: Is Lower Better 8th Annual Orange County Symposium on Cardiovascular Disease Prevention Saturday, October 8, 2016 Keith C. Norris, MD, PhD, FASN Professor of Medicine,
More information5.2 Key priorities for implementation
5.2 Key priorities for implementation From the full set of recommendations, the GDG selected ten key priorities for implementation. The criteria used for selecting these recommendations are listed in detail
More informationDiabetes and Hypertension
Diabetes and Hypertension M.Nakhjvani,M.D Tehran University of Medical Sciences 20-8-96 Hypertension Common DM comorbidity Prevalence depends on diabetes type, age, BMI, ethnicity Major risk factor for
More informationPediatric Hypertension. Alisa A. Acosta, MD, MPH Asst. Professor, Renal Section April 5, 2019
Pediatric Hypertension Alisa A. Acosta, MD, MPH Asst. Professor, Renal Section April 5, 2019 Objectives Recognize the importance of accurate blood pressure measurement in pediatric patients Define pediatric
More informationHypertension 2015: Recent Evidence that Will Change Your Practice
Hypertension 2015: Recent Evidence that Will Change Your Practice Gerald W. Smetana, M.D. Division of General Medicine Beth Israel Deaconess Medical Center Professor of Medicine Harvard Medical School
More informationCombination Therapy for Hypertension
Combination Therapy for Hypertension Se-Joong Rim, MD Cardiology Division, Yonsei University College of Medicine, Seoul, Korea Goals of Therapy Reduce CVD and renal morbidity and mortality. Treat to BP
More informationDisclosures. Learning Objectives. Hypertension: a sprint to the finish Ontario Pharmacists Association 1
Disclosures I have no current or past relationships with commercial entities I have received a speaker s fee from the Ontario Pharmacists Association for this learning activity Laura Tsang PharmD Sunnybrook
More informationManagement of High Blood Pressure in Children and Adolescents
Π.Μ.Σ. «ΜΟΝΑΔΕΣ ΕΝΤΑΤΙΚΗΣ ΘΕΡΑΠΕΙΑΣ - ΚΑΡΔΙΟΛΟΓΙΚΗ ΝΟΣΗΛΕΥΤΙΚΗ» Management of High Blood Pressure in Children and Adolescents ΕΠΙΔΡΑΣΗ ΤΗΣ ΑΝΤΙΥΠΕΡΤΑΣΙΚΗΣ ΑΓΩΓΗΣ ΣΤΗΝ ΑΡΤΗΡΙΑΚΗ ΣΚΛΗΡΙΑ ΥΠΕΡΤΑΣΙΚΩΝ ΑΣΘΕΝΩΝ
More information신장환자의혈압조절 나기영. Factors involved in the regulation of blood pressure
신장환자의혈압조절 K/DOQI Clinical practice guidelines on Hypertension and Antihypertensive agents in CKD 나기영 Factors involved in the regulation of blood pressure Renal function curve MAP (mmhg) Central role of
More informationAngiotensin Converting Enzyme inhibitor (ACEi) / Angiotensin Receptor Blocker (ARB) To STOP OR Not in Advanced Renal Disease
Angiotensin Converting Enzyme inhibitor (ACEi) / Angiotensin Receptor Blocker (ARB) To STOP OR Not in Advanced Renal Disease Investigator Meeting 12 th September 2017 - Sheffield Prof Sunil Bhandari Consultant
More information2014 Evidence-Based HTN Guideline: Preliminary Data from AMGA s Anceta Collaborative
2014 Evidence-Based HTN Guideline: Preliminary Data from AMGA s Anceta Collaborative February 2014 Patient Population Measure spec for MU/PD generally follows NQF 0018 (used for HEDIS, PQRS, and MU) 1.6
More informationSELECTED ABSTRACTS. All (n) % 3-year GS 88% 82% 86% 85% 88% 80% % 3-year DC-GS 95% 87% 94% 89% 96% 80%
SELECTED ABSTRACTS The following are summaries of selected posters presented at the American Transplant Congress on May 5 9, 2007, in San Humar A, Gillingham KJ, Payne WD, et al. Review of >1000 kidney
More informationSTATE OF THE ART BP ASSESSMENT
STATE OF THE ART BP ASSESSMENT PROFESSOR MOLECULAR PHARMACOLOGY CONWAY INSTITUE UNIVERSITY COLLEGE DUBLIN CO-CHAIRMAN BLOOD PRESCSURE MANAGEMENT IN LOW RESOURCE SETTINGS CENTRE FOR INTERNATIONAL HUMANITARIAN
More informationIs Traditional Clinic Blood Pressure Dead?
Royal College of Physicans May 16 th 2017 Is Traditional Clinic Blood Pressure Dead? Professor Bryan Williams MD FRCP FAHA FESC Chair of Medicine UCL Director National Institute for Health Research Biomedical
More informationImpact of Recent Hypertension Guidelines on Clinical Practice
C H A P T E R 144 Impact of Recent Hypertension Guidelines on Clinical Practice NK Soni, VB Jindal The movement towards evidence-based healthcare has been gaining ground quickly over the past few years,
More informationHypertension Update. Objectives 4/28/2015. Beverly J. Mathis, D.O. OOA May 2015
Hypertension Update Beverly J. Mathis, D.O. OOA May 2015 Objectives Learn new recommendations for BP treatment goals Approach to hypertension in the office Use of hypertensive drugs, and how to tailor
More informationCONCORD INTERNAL MEDICINE HYPERTENSION PROTOCOL
CONCORD INTERNAL MEDICINE HYPERTENSION PROTOCOL Douglas G. Kelling Jr., MD Carmella Gismondi-Eagan, MD, FACP George C. Monroe, III, MD Revised, April 8, 2012 The information contained in this protocol
More informationHypertension Update Warwick Jaffe Interventional Cardiologist Ascot Hospital
Hypertension Update 2008 Warwick Jaffe Interventional Cardiologist Ascot Hospital Definition of Hypertension Continuous variable At some point the risk becomes high enough to justify treatment Treatment
More informationNew Lipid Guidelines. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids.
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Disclosure No relevant
More informationManaging Hypertension in 2016
Managing Hypertension in 2016: Where Do We Draw the Line? Disclosure No relevant financial relationships Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu
More informationORIGINAL ARTICLE AMBULATORY BLOOD PRESSURE IN OBESITY. Introduction. Patients and Methods
Vol. 2, Issue 1, pages 31-36 ORIGINAL ARTICLE AMBULATORY BLOOD PRESSURE IN OBESITY By Alejandro de la Sierra, MD Luis M. Ruilope, MD Hypertension Units, Hospital Clinico, Barcelona & Hospital 12 de Octubre,
More informationObjectives. JNC 7 Is Nice But What s Up With JNC 8? Why Do We Care? Hypertension Background: Prevalence
JNC 7 Is Nice But What s Up With JNC 8? 37 th Annual CAPA Conference October 4 th 2013 Ignacio de Artola, Jr. M.D. Assistant Professor of Clinical Family Medicine Medical Director, Primary Care Physician
More informationJNC-8. (Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure- 8) An Update on Hypertension Guidelines
JNC-8 (Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure- 8) An Update on Hypertension Guidelines Derrick Sorweide, DO Assistant Professor of Family Medicine,
More informationBlood Pressure. Michelle Bertram- Nephrology- OBH
Blood Pressure Michelle Bertram- Nephrology- OBH Hypertension- how common? 29-30% white adults 46-51% uncontrolled Diagnosis Two or more properly measured BP s after an initial screen NICE guidelines also
More informationControlling Hypertension in Primary Care: Hitting a moving target?
Controlling Hypertension in Primary Care: Hitting a moving target? David J. Hyman, MD,MPH Professor of Medicine and Family & Community Medicine Chief, Section General Medicine Baylor College of Medicine
More informationTreating Hypertension in 2018: What Makes the Most Sense Today?
Treating Hypertension in 2018: What Makes the Most Sense Today? Daniel Blanchard, MD Professor of Medicine UC San Diego Cardiovascular Center La Jolla, California 1 2 Speaker Disclosures Consultant and/or
More informationAMBULATORY BLOOD PRESSURE REPORT. Patient Name: Sample 2 - Systolic Hypertension Patient ID: Test Date: 15-Sep-2005
Interpretive Summary Based upon JNC 7 and AHA recommendations, the ABPM data suggests 24 hour SYS hypertension (136 mmhg) with normal 24 hour DIA pressure (73 mmhg) Awake SYS hypertension (138 mmhg) with
More informationHypertension. Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute
Hypertension Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute Hypertension 2017 Classification BP Category Systolic Diastolic Normal 120 and 80 Elevated
More informationTreating Hypertension in Individuals with Diabetes
Treating Hypertension in Individuals with Diabetes Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any
More informationManagement of Hypertension. M Misra MD MRCP (UK) Division of Nephrology University of Missouri School of Medicine
Management of Hypertension M Misra MD MRCP (UK) Division of Nephrology University of Missouri School of Medicine Disturbing Trends in Hypertension HTN awareness, treatment and control rates are decreasing
More information2017 AAP Guidelines for Childhood Hypertension
2017 AAP Guidelines for Childhood Hypertension Joseph T. Flynn, MD, MS, FAAP Professor of Pediatrics, University of Washington Chief, Division of Nephrology, Seattle Children s Hospital Disclaimer In the
More informationPatrick Kay, General and Interventional Cardiologist Auckland or healthpoint.co.nz
Patrick Kay, General and Interventional Cardiologist Auckland ipatkay@hotmail.com or healthpoint.co.nz Rotorua 2015 Rotorua 2015 Graphical example of true mean and variation, and of regression to the
More informationQuality ID #122: Adult Kidney Disease: Blood Pressure Management National Quality Strategy Domain: Effective Clinical Care
Quality ID #122: Adult Kidney Disease: Blood Pressure Management National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Intermediate
More informationFructose, Uric Acid and Hypertension in Children and Adolescents
Fructose, Uric Acid and Hypertension in Children and Adolescents Daniel I. Feig, MD, PhD, MS Director, Division of Nephrology Department of Pediatrics University of Alabama, Birmingham Topics for Discussion
More informationManagement of Resistant Hypertension in Diabetes
Management of Resistant Hypertension in Diabetes Soon Hee Lee, M.D., Ph.D. Divisoin of Endocrinology & Metabolism, Department of Internal Medicine, Busan Paik Hospital, College of Medicine, Inje University,
More informationClinical Medical Policy Department Clinical Affairs Division DESCRIPTION
Ambulatory Blood Pressure Monitoring (ABPM) [For the list of services and procedures that need preauthorization, please refer to www.mcs.com.pr. go to Comunicados a Proveedores, and click Cartas Circulares.]
More informationEffective Date: TBD Version: 1.0 (Revised: 6/11/2014)
Protocol Title: Hypertension Effective Date: TBD Version: 1.0 (Revised: 6/11/2014) Approval By: TBD Planned Review Date: TBD 1 Purpose & Objective This protocol provides evidence-based care recommendations
More informationLiterature Review Transplantation
Literature Review 2010- Transplantation Alexander Wiseman, M.D. Associate Professor, Division of Renal Diseases and Hypertension Medical Director, Kidney and Pancreas Transplant Programs University of
More informationPaediatric addendum to the note for guidance on the clinical investigation on medicinal products in the treatment of hypertension
26 February 2015 EMA/CHMP/206815/2013 Committee for Medicinal Products for Human Use (CHMP) Paediatric addendum to the note for guidance on the clinical investigation on medicinal products in the treatment
More informationSalvageability of renal function following renal revascularization in children with Takayasu arteritis-induced renal artery stenosis
Salvageability of renal function following renal revascularization in children with Takayasu arteritis-induced renal artery stenosis Obiagwu P 1, Gajjar P 1, Scott C 1, Numanoglu A 2, McCulloch M, 1 Nourse
More informationCVD Risk Assessment. Michal Vrablík Charles University, Prague Czech Republic
CVD Risk Assessment Michal Vrablík Charles University, Prague Czech Republic What is Risk? A cumulative probability of an event, usually expressed as percentage e.g.: 5 CV events in 00 pts = 5% risk This
More information2020 HYPERTENSION HIGHLIGHTS
2020 HYPERTENSION HIGHLIGHTS A Practical Guide informed by the Hypertension Canada Guidelines for the Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension BLOOD PRESSURE MEASUREMENT TECHNIQUE
More informationHipertensión enmascarada. Alejandro de la Sierra Hospital Mútua Terrassa Universitat de Barcelona
Hipertensión enmascarada Alejandro de la Sierra Hospital Mútua Terrassa Universitat de Barcelona HTA enmascarada Definición Prevalencia Características clínicas Riesgo derivado Asociación con LOD Progresión
More informationPre-ALLHAT Drug Use. Diuretics. ß-Blockers. ACE Inhibitors. CCBs. Year. % of Treated Patients on Medication. CCBs. Beta Blockers.
Pre- Drug Use % of Treated Patients on Medication 60 50 40 30 20 10 0 1978 Diuretics ß-Blockers ACE Inhibitors Year CCBs CCBs Beta Blockers Diuretics ACE Inhibitors 1980 1982 1984 1986 1988 1990 1992 IMS
More informationPredicting and changing the future for people with CKD
Predicting and changing the future for people with CKD I. David Weiner, M.D. Co-holder, C. Craig and Audrae Tisher Chair in Nephrology Professor of Medicine and Physiology and Functional Genomics University
More informationHypertension. Risk of cardiovascular disease beginning at 115/75 mmhg doubles with every 20/10mm Hg increase. (Grade B)
Practice Guidelines and Principles: Guidelines and principles are intended to be flexible. They serve as reference points or recommendations, not rigid criteria. Guidelines and principles should be followed
More informationThe New Hypertension Guidelines
The New Hypertension Guidelines Joseph Saseen, PharmD Professor and Vice Chair, Department of Clinical Pharmacy University of Colorado Anschutz Medical Campus Disclosure Joseph Saseen reports no conflicts
More information